Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported ...

US-based biotechnology company Ocugen has received approval from the Data and Safety Monitoring Board (DSMB) to begin dosing ...

Regeneron Pharmaceuticals has reported positive outcomes from the Phase III QUASAR trial of Eylea HD (aflibercept) 8mg injection in treating individuals with macular oedema following retinal vein ...

It is important to consider the relative efficacy of the available therapies for RVO with published data. This systematic review was therefore performed to assess the efficacy and safety of ...

Further information Decision makers noted that Aflibercept 8mg is clinically equivalent and of at least equal cost-effectiveness to the NICE recommended aflibercept 2mg formulation (TA 346 and TA294).

and diabetic macular oedema (DMO - and will be sold in the EU by Biogen. Like Lucentis, the biosimilar can also be used to treat proliferative diabetic retinopathy (PDR), macular oedema caused by ...

Diabetic macular edema occurs when fluid leaks from blood vessels in the retina, causing swelling in the macula that can lead to vision loss in people with diabetes. Let's explore the latest ...